Humacyte's ATEV Shows Superiority in High-Risk Hemodialysis Patients, Lancet Digital Health Publishes Phase 3 Results — Humacyte, Inc.

Event summary

Humacyte's Phase 3 V007 trial results published in The Lancet Digital Health show ATEV's superiority over autogenous fistulas for hemodialysis access in high-risk patients, including all women and men with obesity and diabetes.
The study, led by Mohamad A. Hussain, M.D., Ph.D. from Mass General Brigham, validates ATEV's benefits for patients with higher risk profiles.
Positive two-year results from V007 and interim V012 results support a planned sBLA submission in H2 2026 to expand Symvess® label for AV access in hemodialysis.
ATEV has received RMAT and Fast Track designations from the FDA for multiple indications, including vascular trauma and PAD.

The big picture

Humacyte's publication in The Lancet Digital Health underscores the growing validation of bioengineered tissues in medical applications, particularly for high-risk patient populations. The company's strategic focus on expanding the use of ATEV beyond vascular trauma to include hemodialysis access positions it at the forefront of regenerative medicine. With multiple RMAT and Fast Track designations, Humacyte is well-positioned to capitalize on the increasing demand for innovative solutions in chronic disease management.

What we're watching

Regulatory Approval: Whether the sBLA submission in H2 2026 will succeed, expanding Symvess®'s label to include AV access for hemodialysis.
Market Adoption: The pace at which ATEV gains market acceptance among high-risk hemodialysis patients, particularly women and those with obesity and diabetes.
Competitive Positioning: How Humacyte's ATEV differentiates itself from existing hemodialysis access solutions in terms of long-term durability and patient outcomes.